GSK breach of undertaking found after repeat digital banner legibility failures (AUTH/3480/3/21)

📅 2021 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/3480/3/21
CompanyGlaxoSmithKline UK Limited
ComplainantConcerned healthcare professional (as described)
IssueAlleged breach of undertaking linked to repeat digital advertising issues (legibility/placement of non-proprietary name) across historic cases
Complaint received1 March 2021
Case completed4 November 2021
AppealNo appeal
Breach clausesClause 9.1; Clause 29
No breach clausesClause 2
SanctionsUndertaking received; Additional sanctions: Not stated
Related cases referencedAUTH/2787/8/15; AUTH/3148/1/19; AUTH/3328/4/20; AUTH/3341/5/20

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A complainant (self-described concerned healthcare professional) cited a third-party LinkedIn post reviewing four historic GSK cases (AUTH/2787/8/15, AUTH/3148/1/19, AUTH/3328/4/20, AUTH/3341/5/20) involving illegibility/placement of non-proprietary names in digital banner advertising.
  • The complainant alleged GSK had recurrently breached similar clauses on similar materials and therefore breached an earlier undertaking (Clause 29).
  • The Authority asked GSK to consider Clauses 2, 9.1 and 29.
  • GSK argued there was no new evidence and that repeated breach of the same clause does not automatically mean breach of an undertaking; each case must be assessed on its facts.
  • The Panel assessed whether later cases were “closely similar” to the original undertaking in AUTH/2787/8/15 and examined root causes and remedial actions.
  • The Panel found AUTH/3148/1/19 was not closely similar (notably due to third-party agency involvement) and so did not breach the earlier undertaking.
  • The Panel found similarities between AUTH/3328/4/20 and AUTH/3341/5/20 and the original case: the later breaches arose because the signatory failed to check the HTML format on the staging site (as required by SOP) in addition to the final PDF, leading to blurry/illegible generic name in the live HTML.
⚖️

Outcome

  • Breach of Clause 29 was ruled (breach of undertaking) in relation to the Avamys cases being sufficiently similar to the earlier undertaking.
  • Breach of Clause 9.1 was ruled because failing to comply with an undertaking meant high standards were not maintained.
  • No breach of Clause 2 was ruled; the Panel considered the breach-of-undertaking concerns were adequately addressed by the Clause 9.1 breach in the circumstances.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training